167 related articles for article (PubMed ID: 17487292)
1. Preventing cardiovascular disease among Canadians: what are the potential benefits of treating hypertension or dyslipidemia?
Grover SA; Coupal L; Kaouache M; Lowensteyn I
Can J Cardiol; 2007 May; 23(6):467-73. PubMed ID: 17487292
[TBL] [Abstract][Full Text] [Related]
2. Preventing cardiovascular disease among Canadians: is the treatment of hypertension or dyslipidemia cost-effective?
Grover S; Coupal L; Lowensteyn I
Can J Cardiol; 2008 Dec; 24(12):891-8. PubMed ID: 19052668
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor.
Grover SA; Coupal L; Zowall H; Weiss TW; Alexander CM
Am J Med; 2003 Aug; 115(2):122-8. PubMed ID: 12893398
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of hypertension therapy according to 2014 guidelines.
Moran AE; Odden MC; Thanataveerat A; Tzong KY; Rasmussen PW; Guzman D; Williams L; Bibbins-Domingo K; Coxson PG; Goldman L
N Engl J Med; 2015 Jan; 372(5):447-55. PubMed ID: 25629742
[TBL] [Abstract][Full Text] [Related]
5. Population health impact of statin treatment in Canada.
Hennessy DA; Tanuseputro P; Tuna M; Bennett C; Perez R; Shields M; Ko DT; Tu J; Manuel DG
Health Rep; 2016 Jan; 27(1):20-8. PubMed ID: 26788719
[TBL] [Abstract][Full Text] [Related]
6. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
7. Dyslipidemia prevalence, treatment, control, and awareness in the Canadian Health Measures Survey.
Joffres M; Shields M; Tremblay MS; Connor Gorber S
Can J Public Health; 2013 Apr; 104(3):e252-7. PubMed ID: 23823891
[TBL] [Abstract][Full Text] [Related]
8. Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?
Grover SA; Coupal L; Lowensteyn I
Can J Cardiol; 2008 Apr; 24(4):261-6. PubMed ID: 18401465
[TBL] [Abstract][Full Text] [Related]
9. Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy Model.
Moise N; Huang C; Rodgers A; Kohli-Lynch CN; Tzong KY; Coxson PG; Bibbins-Domingo K; Goldman L; Moran AE
Hypertension; 2016 Jul; 68(1):88-96. PubMed ID: 27181996
[TBL] [Abstract][Full Text] [Related]
10. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?
Grover SA; Coupal L; Zowall H; Alexander CM; Weiss TW; Gomes DR
Diabetes Care; 2001 Jan; 24(1):45-50. PubMed ID: 11194239
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Comorbidity Treatment and Costs Associated With Bariatric Surgery Among Adults With Obesity in Canada.
Davis JA; Saunders R
JAMA Netw Open; 2020 Jan; 3(1):e1919545. PubMed ID: 31951277
[TBL] [Abstract][Full Text] [Related]
12. Associations Between Cardiovascular Risk Factors and Audiometric Hearing: Findings From the Canadian Longitudinal Study on Aging.
Mick PT; Kabir R; Pichora-Fuller MK; Jones C; Moxham L; Phillips N; Urry E; Wittich W
Ear Hear; 2023 Nov-Dec 01; 44(6):1332-1343. PubMed ID: 37122082
[TBL] [Abstract][Full Text] [Related]
13. Relationship between adherence level to statins, clinical issues and health-care costs in real-life clinical setting.
Dragomir A; Côté R; White M; Lalonde L; Blais L; Bérard A; Perreault S
Value Health; 2010; 13(1):87-94. PubMed ID: 19695008
[TBL] [Abstract][Full Text] [Related]
14. Comparing Guidelines for Statin Treatment in Canada and the United States.
Hennessy DA; Bushnik T; Manuel DG; Anderson TJ
J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26175357
[TBL] [Abstract][Full Text] [Related]
15. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
Milne RJ; Vander Hoorn S; Jackson RT
Pharmacoeconomics; 1997 Sep; 12(3):384-408. PubMed ID: 10170463
[TBL] [Abstract][Full Text] [Related]
16. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?
Grover SA; Ho V; Lavoie F; Coupal L; Zowall H; Pilote L
Arch Intern Med; 2003 Feb; 163(3):333-9. PubMed ID: 12578514
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease.
Lowensteyn I; Coupal L; Zowall H; Grover SA
J Cardiopulm Rehabil; 2000; 20(3):147-55. PubMed ID: 10860196
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
Grover SA; Coupal L; Paquet S; Zowall H
Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
[TBL] [Abstract][Full Text] [Related]
20. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
Grover SA; Coupal L; Zowall H
Hypertension; 2005 Jan; 45(1):92-7. PubMed ID: 15545508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
